| abstract |
The invention relates to compounds of general formula (I) wherein R is hydrogen, lower alkyl, lower alkoxy, halogen, amino, -N(R6)2 or trifluoromethyl; R1 is hydrogen, lower alkoxy or halogen; R and R1 may be together -CH=CH-CH=CH-; R2 is halogen, lower alkyl or trifluoromethyl; R3 is hydrogen or lower alkyl; R4 is hydrogen or a cyclic tertiary amine, optionally substituted by lower alkyl; R5 is hydrogen, nitro, amino or -N(R6)2; R6 is hydrogen or lower alkyl; X is -C(O)N(R6)-, -(CH¿2?)nO-, -(CH2)nN(R?6¿)-, -N(R6)C(O)- or -N(R6)(CH2)n-; and n is 1 or 2; and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I may be used for the treatment of diseases related to the NK-1 receptor. |